Maurizio Pellecchia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maurizio Pellecchia has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
John L. Stebbins
Cancer Research Center, Sanford‐Burnham Medical Research Institute, 10901 N. Torrey Pines Rd., La Jolla, CA 92037 (USA)
8 shared publicationsElisa Barile
Cancer Research Center, Sanford-Burnham Medical Research Institute, 10901 N. Torrey Pines Rd., La Jolla, CA 92037 (USA)
7 shared publicationsZiming Zhang
Infectious Diseases and Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA
7 shared publicationsBainan Wu
Signal Transduction Program and Cell Death Program, Cancer Center, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
6 shared publicationsSurya K. De
Signal Transduction Program and Cell Death Program, Cancer Center, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
6 shared publications- Roberta Noberini
Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy
5 shared publications
Latest Publications
- Open Access
- 12 September 2014
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 50 (83) , 12578
Correction: A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication
Correction for ‘A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication’ by Mi-Kyung Lee et al., Chem. Commun., 2014, 50, 368–370.
- 12 September 2014
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 50 (83) , 12578
Open AccessCorrection: A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication
Correction for ‘A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication’ by Mi-Kyung Lee et al., Chem. Commun., 2014, 50, 368–370.
- Open Access
- 2 July 2014
- Published by Wiley in ChemMedChem
- Vol. 9 (7) , 1333
Cover Picture: Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System (ChemMedChem 7/2014)
- 2 July 2014
- Published by Wiley in ChemMedChem
- Vol. 9 (7) , 1333
Open AccessCover Picture: Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System (ChemMedChem 7/2014)
- 26 March 2014
- Published by Wiley in ChemMedChem
- Vol. 9 (7) , 1403-1412
Design, Synthesis and Bioevaluation of an EphA2 Receptor‐Based Targeted Delivery System
Because of its overexpression in a range of solid tumors, the EphA2 receptor is a validated target for cancer therapeutics. We recently described a new targeted delivery system based on specific EphA2‐targeting peptides conjugated with the chemotherapeutic agent paclitaxel. Here, we investigate the chemical determinants responsible for the stability and degradation of these agents in plasma. Introducing modifications in both the peptide and the linker between the peptide and paclitaxel resulted in drug conjugates that are both long‐lived in rat plasma and that markedly decrease tumor size in a prostate cancer xenograft model compared with paclitaxel alone treatment. These studies identify critical rate‐limiting degradation sites on the peptide–drug conjugates, enabling the design of agents with increased stability and efficacy. These results provide support for our central hypothesis that peptide–drug conjugates targeting EphA2 represent an innovative and potentially effective strategy to selectively deliver cytotoxic drugs to cancer cells.
- 26 March 2014
- Published by Wiley in ChemMedChem
- Vol. 9 (7) , 1403-1412
Design, Synthesis and Bioevaluation of an EphA2 Receptor‐Based Targeted Delivery System
Because of its overexpression in a range of solid tumors, the EphA2 receptor is a validated target for cancer therapeutics. We recently described a new targeted delivery system based on specific EphA2‐targeting peptides conjugated with the chemotherapeutic agent paclitaxel. Here, we investigate the chemical determinants responsible for the stability and degradation of these agents in plasma. Introducing modifications in both the peptide and the linker between the peptide and paclitaxel resulted in drug conjugates that are both long‐lived in rat plasma and that markedly decrease tumor size in a prostate cancer xenograft model compared with paclitaxel alone treatment. These studies identify critical rate‐limiting degradation sites on the peptide–drug conjugates, enabling the design of agents with increased stability and efficacy. These results provide support for our central hypothesis that peptide–drug conjugates targeting EphA2 represent an innovative and potentially effective strategy to selectively deliver cytotoxic drugs to cancer cells.
- 29 October 2013
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 50 (3) , 368-370
A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication
Through screening by NMR spectroscopy, we discovered a novel scaffold (DPQ: 6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine) that binds specifically to the influenza A virus RNA promoter. The solution structure of the RNA–DPQ complex reported here demonstrates that the internal loop is the binding site of DPQ. The scaffold exhibits antiviral activity against influenza viruses.
- 29 October 2013
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 50 (3) , 368-370
A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication
Through screening by NMR spectroscopy, we discovered a novel scaffold (DPQ: 6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine) that binds specifically to the influenza A virus RNA promoter. The solution structure of the RNA–DPQ complex reported here demonstrates that the internal loop is the binding site of DPQ. The scaffold exhibits antiviral activity against influenza viruses.
- 1 August 2013
- Published by Elsevier in Chemistry & Biology
- Vol. 20 (8) , 973-982
Structure-Based Design of Covalent Siah Inhibitors
- 1 August 2013
- Published by Elsevier in Chemistry & Biology
- Vol. 20 (8) , 973-982
Structure-Based Design of Covalent Siah Inhibitors
- 21 June 2013
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 82 (5) , 520-533
Synthesis and SAR Studies of Dual AKT/NF‐κB Inhibitors Against Melanoma
The protein Kinase B alpha (AKT) and nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathways are central regulators of cellular signaling events at the basis of tumor development and progression. Both pathways are often up‐regulated in different tumor types including melanoma. We recently reported the identification of compound 1 (BI‐69A11) as inhibitor of the AKT and the NF‐κB pathways. Here, we describe SAR studies that led to novel fluorinated derivatives with increased cellular potency, reflected in efficient inhibition of AKT and IKKs. Selected compounds demonstrated effective toxicity on melanoma, breast, and prostate cell lines. Finally, a representative derivative showed promising efficacy in an in vivo melanoma xenograft model.
- 21 June 2013
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 82 (5) , 520-533
Synthesis and SAR Studies of Dual AKT/NF‐κB Inhibitors Against Melanoma
The protein Kinase B alpha (AKT) and nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathways are central regulators of cellular signaling events at the basis of tumor development and progression. Both pathways are often up‐regulated in different tumor types including melanoma. We recently reported the identification of compound 1 (BI‐69A11) as inhibitor of the AKT and the NF‐κB pathways. Here, we describe SAR studies that led to novel fluorinated derivatives with increased cellular potency, reflected in efficient inhibition of AKT and IKKs. Selected compounds demonstrated effective toxicity on melanoma, breast, and prostate cell lines. Finally, a representative derivative showed promising efficacy in an in vivo melanoma xenograft model.
- 1 January 2013
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (1) , 128-137
Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells
Purpose: YSA is an EphA2-targeting peptide that effectively delivers anticancer agents to prostate cancer tumors. Here, we report on how we increased the drug-like properties of this delivery system. Experimental Design: By introducing non-natural amino acids, we have designed two new EphA2 targeting peptides: YNH, where norleucine and homoserine replace the two methionine residues of YSA, and dYNH, where a D-tyrosine replaces the L-tyrosine at the first position of the YNH peptide. We describe the details of the synthesis of YNH and dYNH paclitaxel conjugates (YNH-PTX and dYNH-PTX) and their characterization in cells and in vivo. Results: dYNH-PTX showed improved stability in mouse serum and significantly reduced tumor size in a prostate cancer xenograft model and also reduced tumor vasculature in a syngeneic orthotopic allograft mouse model of renal cancer compared with vehicle or paclitaxel treatments. Conclusion: This study reveals that targeting EphA2 with dYNH drug conjugates could represent an effective way to deliver anticancer agents to a variety of tumor types. Clin Cancer Res; 19(1); 128–37. ©2012 AACR.
- 1 January 2013
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (1) , 128-137
Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells
Purpose: YSA is an EphA2-targeting peptide that effectively delivers anticancer agents to prostate cancer tumors. Here, we report on how we increased the drug-like properties of this delivery system. Experimental Design: By introducing non-natural amino acids, we have designed two new EphA2 targeting peptides: YNH, where norleucine and homoserine replace the two methionine residues of YSA, and dYNH, where a D-tyrosine replaces the L-tyrosine at the first position of the YNH peptide. We describe the details of the synthesis of YNH and dYNH paclitaxel conjugates (YNH-PTX and dYNH-PTX) and their characterization in cells and in vivo. Results: dYNH-PTX showed improved stability in mouse serum and significantly reduced tumor size in a prostate cancer xenograft model and also reduced tumor vasculature in a syngeneic orthotopic allograft mouse model of renal cancer compared with vehicle or paclitaxel treatments. Conclusion: This study reveals that targeting EphA2 with dYNH drug conjugates could represent an effective way to deliver anticancer agents to a variety of tumor types. Clin Cancer Res; 19(1); 128–37. ©2012 AACR.
- 1 January 2013
- Published by Elsevier in Chemistry & Biology
- Vol. 20 (1) , 19-33
HTS by NMR of Combinatorial Libraries: A Fragment-Based Approach to Ligand Discovery
- 1 January 2013
- Published by Elsevier in Chemistry & Biology
- Vol. 20 (1) , 19-33
HTS by NMR of Combinatorial Libraries: A Fragment-Based Approach to Ligand Discovery
- 8 November 2012
- Published by Wiley in ChemMedChem
- Vol. 7 (12) , 2227-2235
Identification of Small Molecules that Interfere with H1N1 Influenza A Viral Replication
Successful replication of the influenza A virus requires both viral proteins and host cellular factors. In this study we used a cellular assay to screen for small molecules capable of interfering with any of such necessary viral or cellular components. We used an established reporter assay to assess influenza viral replication by monitoring the activity of co‐expressed luciferase. We screened a diverse chemical compound library, resulting in the identification of compound 7, which inhibits a novel yet elusive target. Quantitative real‐time PCR studies confirmed the dose‐dependent inhibitory activity of compound 7 in a viral replication assay. Furthermore, we showed that compound 7 is effective in rescuing high‐dose influenza infection in an in vivo mouse model. As oseltamivir‐resistant influenza strains emerge, compound 7 could be further investigated as a new and potentially suitable scaffold for the development of anti‐influenza agents that act on novel targets.
- 8 November 2012
- Published by Wiley in ChemMedChem
- Vol. 7 (12) , 2227-2235
Identification of Small Molecules that Interfere with H1N1 Influenza A Viral Replication
Successful replication of the influenza A virus requires both viral proteins and host cellular factors. In this study we used a cellular assay to screen for small molecules capable of interfering with any of such necessary viral or cellular components. We used an established reporter assay to assess influenza viral replication by monitoring the activity of co‐expressed luciferase. We screened a diverse chemical compound library, resulting in the identification of compound 7, which inhibits a novel yet elusive target. Quantitative real‐time PCR studies confirmed the dose‐dependent inhibitory activity of compound 7 in a viral replication assay. Furthermore, we showed that compound 7 is effective in rescuing high‐dose influenza infection in an in vivo mouse model. As oseltamivir‐resistant influenza strains emerge, compound 7 could be further investigated as a new and potentially suitable scaffold for the development of anti‐influenza agents that act on novel targets.
- 14 October 2012
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 17 (1) , 61-75
Targeting the Bcl-2 family for cancer therapy
Introduction: Programmed cell death is well-orchestrated process regulated by multiple pro-apoptotic and anti-apoptotic genes, particularly those of the Bcl-2 gene family. These genes are well docu...
- 14 October 2012
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 17 (1) , 61-75
Targeting the Bcl-2 family for cancer therapy
Introduction: Programmed cell death is well-orchestrated process regulated by multiple pro-apoptotic and anti-apoptotic genes, particularly those of the Bcl-2 gene family. These genes are well docu...